Is there a place for sigmoidoscopy in colorectal cancer screening? A systematic review and critical appraisal of cost-effectiveness models.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 13 03 2023
accepted: 05 08 2023
medline: 21 8 2023
pubmed: 18 8 2023
entrez: 18 8 2023
Statut: epublish

Résumé

Screening for colorectal cancer (CRC) is effective in reducing both incidence and mortality. Colonoscopy and stool tests are most frequently used for this purpose. Sigmoidoscopy is an alternative screening measure with a strong evidence base. Due to its distinct characteristics, it might be preferred by subgroups. The aim of this systematic review is to analyze the cost-effectiveness of sigmoidoscopy for CRC screening compared to other screening methods and to identify influencing parameters. A systematic literature search for the time frame 01/2010-01/2023 was conducted using the databases MEDLINE, Embase, EconLit, Web of Science, NHS EED, as well as the Cost-Effectiveness Registry. Full economic analyses examining sigmoidoscopy as a screening measure for the general population at average risk for CRC were included. Incremental cost-effectiveness ratios were calculated. All included studies were critically assessed based on a questionnaire for modelling studies. Twenty-five studies are included in the review. Compared to no screening, sigmoidoscopy is a cost-effective screening strategy for CRC. When modelled as a single measure strategy, sigmoidoscopy is mostly dominated by colonoscopy or modern stool tests. When combined with annual stool testing, sigmoidoscopy in 5-year intervals is more effective and less costly than the respective strategies alone. The results of the studies are influenced by varying assumptions on adherence, costs, and test characteristics. The combination of sigmoidoscopy and stool testing represents a cost-effective screening strategy that has not received much attention in current guidelines. Further research is needed that goes beyond a narrow focus on screening technology and models different, preference-based participation behavior in subgroups.

Identifiants

pubmed: 37594967
doi: 10.1371/journal.pone.0290353
pii: PONE-D-23-07104
pmc: PMC10438011
doi:

Types de publication

Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0290353

Informations de copyright

Copyright: © 2023 Diedrich et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Gut. 2015 Oct;64(10):1637-49
pubmed: 26041752
Cancer Causes Control. 2014 Oct;25(10):1329-36
pubmed: 25048603
Gastroenterology. 2010 Oct;139(4):1128-37
pubmed: 20600026
BMJ. 2017 Jan 13;356:i6673
pubmed: 28087510
Br J Cancer. 2012 Feb 28;106(5):805-16
pubmed: 22343624
J Med Screen. 2015 Sep;22(3):119-26
pubmed: 25967088
Therap Adv Gastroenterol. 2020 Sep 20;13:1756284820953364
pubmed: 33014138
Patient. 2014;7(3):271-82
pubmed: 24652475
N Engl J Med. 2005 May 19;352(20):2061-8
pubmed: 15901859
Cancer. 2017 May 1;123(9):1516-1527
pubmed: 28117881
Z Gastroenterol. 2019 Sep;57(9):1059-1066
pubmed: 31525798
Endoscopy. 2011 Dec;43(12):1059-86
pubmed: 22135196
PLoS One. 2019 Dec 31;14(12):e0227251
pubmed: 31891647
Cancer Control. 2015 Apr;22(2):248-58
pubmed: 26068773
Patient Prefer Adherence. 2018 Oct 31;12:2267-2282
pubmed: 30464417
JAMA. 2021 May 18;325(19):1978-1998
pubmed: 34003220
Value Health. 2014 Mar;17(2):174-82
pubmed: 24636375
Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1043-51
pubmed: 23632815
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
PLoS One. 2019 Sep 4;14(9):e0220234
pubmed: 31483796
Scand J Gastroenterol. 2012 Feb;47(2):184-90
pubmed: 22229966
Value Health. 2019 Sep;22(9):1026-1032
pubmed: 31511179
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001216
pubmed: 17253456
Clin Gastroenterol Hepatol. 2012 Mar;10(3):266-71.e1-6
pubmed: 22100624
Expert Rev Med Devices. 2013 Jul;10(4):489-99
pubmed: 23895076
World J Gastroenterol. 2017 May 28;23(20):3632-3642
pubmed: 28611516
Epidemiol Rev. 2011;33:88-100
pubmed: 21633092
BMJ. 2014 Apr 09;348:g2467
pubmed: 24922745
Ann Intern Med. 2018 Jun 5;168(11):775-782
pubmed: 29710125
Pharmacoeconomics. 2004;22(13):857-76
pubmed: 15329031
Endoscopy. 2011 Sep;43(9):780-93
pubmed: 21623557
J Med Screen. 2019 Jun;26(2):76-83
pubmed: 30180780
PLoS Med. 2010 Nov 23;7(11):e1000370
pubmed: 21124887
Value Health. 2018 Jul;21(7):858-873
pubmed: 30005759
Am J Gastroenterol. 2013 Jan;108(1):120-32
pubmed: 23247579
J Med Screen. 2011;18(3):128-34
pubmed: 22045821
Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1567-76
pubmed: 23796793
Risk Manag Healthc Policy. 2020 Sep 10;13:1499-1512
pubmed: 32982508
Gastroenterology. 2019 Jul;157(1):137-148
pubmed: 30930021
Health Econ Rev. 2013 Sep 12;3(1):20
pubmed: 24229442
Colorectal Dis. 2012 Sep;14(9):e547-61
pubmed: 22390210
Appl Health Econ Health Policy. 2010;8(3):141-54
pubmed: 20369905
Endoscopy. 2013;45(2):142-50
pubmed: 23335011
BMJ Open. 2019 Oct 2;9(10):e032773
pubmed: 31578199
World J Gastroenterol. 2018 Jan 7;24(1):124-138
pubmed: 29358889
Med J Aust. 2014 Nov 3;201(9):523-7
pubmed: 25358576
Medicine (Baltimore). 2016 Mar;95(10):e2739
pubmed: 26962772
CMAJ. 2010 Sep 7;182(12):1307-13
pubmed: 20624866
PLoS One. 2016 Dec 9;11(12):e0167452
pubmed: 27936028
Am J Gastroenterol. 2018 Dec;113(12):1836-1847
pubmed: 29904156
N Engl J Med. 2012 Feb 23;366(8):697-706
pubmed: 22356323
Arch Intern Med. 2003 Feb 24;163(4):413-20
pubmed: 12588199
Clin Gastroenterol Hepatol. 2013 Sep;11(9):1158-66
pubmed: 23542330
Ann Intern Med. 2009 Jan 6;150(1):1-8
pubmed: 19075198
Cancer Detect Prev. 2006;30(4):347-53
pubmed: 16965874
Int J Cancer. 2018 Jul 15;143(2):269-282
pubmed: 29441568
J Natl Cancer Inst. 2010 Aug 18;102(16):1238-52
pubmed: 20664028
Radiology. 2011 Nov;261(2):487-98
pubmed: 21813740
Ann Intern Med. 2010 Sep 21;153(6):368-77
pubmed: 20855801
Clin Gastroenterol Hepatol. 2019 Sep;17(10):1969-1981.e15
pubmed: 30659991
Ann Intern Med. 2014 Jun 3;160(11):750-9
pubmed: 24887616
N Engl J Med. 2022 Oct 27;387(17):1547-1556
pubmed: 36214590
Gastroenterology. 2010 Jun;138(6):2088-100
pubmed: 20420948
Hong Kong Med J. 2015 Dec;21 Suppl 6:4-8
pubmed: 26645874
Cost Eff Resour Alloc. 2018 Jun 07;16:20
pubmed: 29977160

Auteurs

Leonie Diedrich (L)

Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany.

Melanie Brinkmann (M)

Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany.

Maren Dreier (M)

Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany.

Siegbert Rossol (S)

Department of Internal Medicine, Krankenhaus Nordwest, Frankfurt/M, Germany.

Wendelin Schramm (W)

GECKO Institute for Medicine, Informatics and Economics, Heilbronn University, Heilbronn, Germany.

Christian Krauth (C)

Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH